Pediatric Pneumococcal Infections Treatment & Management

1. Stockmann C, Ampofo K, Byington CL, Filloux F, Hersh AL, Blaschke AJ, et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah. Pediatrics. 2013 Sep. 132(3):421-8. [Medline].

2. Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. 2013 Oct. 19 Suppl 1:1-9. [Medline].

3. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Mar. 32(3):203-7. [Medline].

4. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in cleveland, ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis. 2008. 47:1388-95. [Medline].

5. Jacobs MR, Bajaksouzian S, Bonomo RA, et al. Occurrence, distribution and origins of serotype 6C Streptococcus pneumoniae, a recently recognized serotype. J Clin Microbiol. 2008 Oct 29. [Medline].

6. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008 Feb 15. 57(6):144-8. [Medline]. [Full Text].

7. Ulloa-Gutierrez R, Avila-Aguero ML. 6th International Symposium on Pneumococci and Pneumococcal Diseases. Expert Rev Vaccines. 2008 Aug. 7(6):725-8. [Medline]. [Full Text].

8. Greenhow TL, Hung YY, Herz A. Bacteremia in Children 3 to 36 Months Old After Introduction of Conjugated Pneumococcal Vaccines. Pediatrics. 2017 Apr. 139 (4):[Medline].

9. Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI, Members of the Massachusetts Department of Public Health. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics. 2015 Mar. 135 (3):495-503. [Medline].

10. Barclay L. Pneumococcal Vaccine May Not Prevent Invasive Disease in Kids. Medscape Medical News. Available at http://www.medscape.com/viewarticle/839127. February 03, 2015; Accessed: September 11, 2015.

11. Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics. 1998 Nov. 102(5):1087-97. [Medline].

12. FDA. FDA Approves Pneumococcal Disease Vaccine with Broader Protection. US Food and Drug Administration. February 24, 2010. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm201667.htm.

13. Putre L. Older High-Risk Children Should Receive PCV13, AAP Says. Medscape Medical News. Available at http://www.medscape.com/viewarticle/835366. Accessed: November 26, 2014.

14. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016 May. 4 (5):399-406. [Medline].

15. van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009 Jul 8. 302(2):159-67. [Medline].

16. Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, Goldblatt D. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis. 2011 Oct. 53(7):663-70. [Medline]. [Full Text].

17. Christie D, Viner RM, Knox K, et al. Long-term outcomes of pneumococcal meningitis in childhood and adolescence. Eur J Pediatr. 2011 Aug. 170(8):997-1006. [Medline].

18. Hand L. Four PCV vaccine schedules similarly protect infants. Medscape Medical News. September 3, 2013;. Available at http://www.medscape.com/viewarticle/810376. Accessed: September 9, 2013.

19. Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013 Sep 4. 310(9):930-7. [Medline].

20. AAPCID. Pneumococcal infections. Pickering LK, ed. 2009 Red Book: Report of the Committee on Infectious Diseases. 28th ed. American Academy of Pediatrics; 2009. 524-535.

21. AAPCID. Therapy for children with invasive pneumococcal infections. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 1997 Feb. 99(2):289-99. [Medline].

22. Abramowicz M. A pneumococcal conjugate vaccine for infants and children. Med Lett Drugs Ther. 2000 Mar 20. 42(1074):25-7. [Medline].

23. Barclay, L. PCV-13 May Not Fully Protect Children With Comorbidity. Medscape Medical News. Available at http://www.medscape.com/viewarticle/827886. Accessed: July 8, 2014.

24. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000 Mar. 19(3):187-95. [Medline].

25. Bradley JS, Kaplan SL, Tan TQ, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics. 1998 Dec. 102(6):1376-82. [Medline].

26. Brown T. ACIP Approves 2014 Child/Adolescent Immunization Schedule. Medscape Medical news. Available at http://www.medscape.com/viewarticle/813092. Accessed: October 28, 2013.

27. Copelovitch L, Kaplan BS. Streptococcus pneumoniae--associated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics. 2010 Jan. 125(1):e174-82. [Medline].

28. Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr Opin Otolaryngol Head Neck Surg. 2004 Dec. 12(6):488-94. [Medline].

29. Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae.The Streptococcus pneumoniae Working Group. Pediatrics. 1999 Feb. 103(2):409-13. [Medline].

30. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11. 331(6):377-82. [Medline].

31. Gertz RE Jr, Li Z, Pimenta FC, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis. 2010 Mar. 201(5):770-5. [Medline].

32. Kaplan SL, Mason EO Jr, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics. 1998 Sep. 102(3 Pt 1):538-45. [Medline].

33. Klein JO. The pneumococcal conjugate vaccine arrives: a big win for kids. Pediatr Infect Dis J. 2000 Mar. 19(3):181-2. [Medline].

34. Levine OS, Farley M, Harrison LH, et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999 Mar. 103(3):E28. [Medline].

35. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010 Jan. 125(1):26-33. [Medline].

36. O'Brien KL, Santosham M. Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases. Am J Epidemiol. 2004 Apr 1. 159(7):634-44. [Medline].

37. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006 Apr 12. 295(14):1668-74. [Medline].

38. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA. 2001 Apr 4. 285(13):1729-35. [Medline].

39. Rubin LG. Pneumococcal vaccine. Pediatr Clin North Am. 2000 Apr. 47(2):269-85, v. [Medline].

40. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J. 2000 Apr. 19(4):394-7. [Medline].

41. Siberry GK, Iannone R. Formulary. Johns Hopkins University, ed. The Harriet Lane Handbook: A Manual for Pediatric House Officers. 18 ed. Mosby-Year Book; 2008. 697-1030.

42. Steenhoff AP, Shah SS, Ratner AJ, et al. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006 Apr 1. 42(7):907-14. [Medline].

43. Tan TQ, Mason EO Jr, Barson WJ, et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics. 1998 Dec. 102(6):1369-75. [Medline].

44. Teele DW. Pneumococcal infections. Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia, PA: WB Saunders Co; 2005. Vol 1:

45. Todd JK. Streptococcus pneumoniae (Pneumococcus). In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: WB Saunders Co. 2007.

46. Toltzis P, Jacobs MR. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use. Infect Dis Clin North Am. 2005 Sep. 19(3):629-45. [Medline].

47. Wadwa RP, Feigin RD. Pneumococcal vaccine: an update. Pediatrics. 1999 May. 103(5 Pt 1):1035-7. [Medline].

48. Johansson Kostenniemi U, Palm J, Silfverdal SA. Reductions in otitis and other respiratory tract infections following childhood pneumococcal vaccination. Acta Paediatr. 2018 Mar 30. [Medline].

Meera Varman, MD Associate Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, Creighton University Medical Center

Meera Varman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Healthcare Epidemiology of America

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Pfizer, Sanofi<br/>Received research grant from: Merck; MedImmune; Regenron; Pfizer;Novartis; Sanof; GSK<br/>Received honoraria from phamaceutical companies for speaking and teaching; Received grant/research funds from phamaceutical companies for clinical trials research.

Archana Chatterjee, MD, PhD Professor and Chair, Department of Pediatrics, Senior Associate Dean for Faculty Development, Sanford School of Medicine, The University of South Dakota

Archana Chatterjee, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, International Society for Infectious Diseases, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Larry I Lutwick, MD, FACP Editor-in-Chief, ID Cases; Moderator, Program for Monitoring Emerging Diseases; Adjunct Professor of Medicine, State University of New York Downstate College of Medicine

Larry I Lutwick, MD, FACP is a member of the following medical societies: American Association for the Advancement of Science, American Association for the Study of Liver Diseases, American College of Physicians, American Federation for Clinical Research, American Society for Microbiology, Infectious Diseases Society of America, Infectious Diseases Society of New York, International Society for Infectious Diseases, New York Academy of Sciences, Veterans Affairs Society of Practitioners in Infectious Diseases

Disclosure: Nothing to disclose.

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Chandy C John, MD, MS Director, Division for Global Pediatrics, Associate Professor of Pediatrics and Medicine, University of Minnesota Medical School

Disclosure: Nothing to disclose.

Nancy A Wick, MD Consulting Staff, Department of Emergency Medicine, Section of Pediatrics, Children's at Scottish Rite

Nancy A Wick, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article